Nature Reviews Drug Discovery
Nature Portfolio · Pharmacology & Drug Discovery · ISSN 1474-1776, 1474-1784
- Impact (2-yr)
- 16.5
- h-index
- 508
- Open access
- 13%
- Works
- 6.9K
- Papers this month
- 9
Rebuilt
Latest in Nat Rev Drug Discov
Newest first · last 60 days
AI summary · may contain errors
A forward-looking NAM framework is proposed to adapt mathematically modeled, AI, organ-on-a-chip, and advanced in vitro/ex vivo tools for predicting immunogenicity risks of gene therapies, cell treatments, and gene editors.
AI summary · may contain errors
Kinase drug discovery has expanded into a diverse therapeutic landscape with over 150 regulatory approvals worldwide and more than 2,100 kinase-targeting agents in clinical development.
AI summary · may contain errors
Histone lysine demethylases (KDMs), discovered with LSD1 (KDM1A) over two decades ago, have emerged as key regulators of chromatin and gene expression, with clinical LSD1 inhibitors advancing.
AI summary · may contain errors
Conditional biologics engineered to activate in response to tumour-associated signals or within the tumour microenvironment are proposed to uncouple efficacy from toxicity in cancer immunotherapy.
AI summary · may contain errors
Evidence of clinically relevant impact from artificial intelligence in drug discovery remains disappointingly limited despite a decade of growing interest and many developed, applied, and benchmarked methods.
AI summary · may contain errors
Precision psychiatry aligns drug development with neural-biology dysfunctions using biomarkers, leveraging patient-specific brain and peripheral measures to stratify patients and predict treatment response.
AI summary · may contain errors
Transcriptional CDKs are emerging therapeutic candidates because they regulate RNAPII transcription across initiation, elongation, termination, and later stages, enabling targetable vulnerabilities in cancer.
AI summary · may contain errors
A decade of progress since 2016 has advanced cytosine base editors into optimized gene-editing platforms, now deployed in clinical trials across multiple human indications.
AI summary · may contain errors
Immune cell engagers (ICEs) are a modular approach that can achieve deep depletion of pathogenic B cell populations in systemic autoimmune diseases, including long-lived plasma cells.
AI summary · may contain errors
T follicular helper (T FH ) cells sustain long-lasting antibody responses by supporting memory B cell differentiation, enabling immunity that protects hosts from subsequent infections.
AI summary · may contain errors
mRNA therapeutics are poised for a “2.0” era as clinical studies identify key barriers and emerging technical advances, including immune-silent formulations enabling repeated dosing.
AI summary · may contain errors
Simulation-guided trial design can optimize complex clinical trial strategies by evaluating operating characteristics, including type I error, false discovery rate, power, and interim adaptive decision probabilities.
AI summary · may contain errors
Soft drugs are rationally designed to undergo predictable, rapid metabolic inactivation after therapeutic action, improving safety while preserving efficacy in systemic and topical use.
AI summary · may contain errors
Cell surface RNA-binding proteins with cell-type and disease-specific localization are emerging as potential biomarker and immunotherapy targets across cancers and other diseases.
AI summary · may contain errors
Classic and trans-signalling by interleukin-6 (IL-6) through membrane-bound IL-6R versus soluble IL-6R (sIL-6R) is linked to distinct disease roles, shaping selective targeting strategies.
AI summary · may contain errors
Over the past 25 years, drug discovery has expanded its target landscape to 686 biomolecules modulated by 1,702 drugs, reflecting major shifts in target types.
Browse JClub
Journals this month
- bioRxiv6471
- medRxiv1747
- PNAS583
- JAMA366
- Sci Adv330
- Cell Rep320
- Environ Res230
- BMJ208
- EHJ208
- NAR176
- Plant Cell Environ173
- Nat Commun166
- Science152
- Environ Pollution151
- NEJM148
- New Phytol148
- Lancet129
- Nature127
Topics moving, week to 18 Nov 2026
- Gut microbiota and health9
- Single-cell and spatial transcriptomics6
- CAR-T cell therapy research4
- Global Cancer Incidence and Screening3
- Lung Cancer Treatments and Mutations3
- Pancreatic and Hepatic Oncology Research3
- Antibiotic Resistance in Bacteria3
- Bacteriophages and microbial interactions3
- Diabetes Management and Education3
- Immune cells in cancer3
By field
- General Science & Medicine22
- Clinical Medicine25
- Cardiology & Vascular Biology12
- Endocrinology & Metabolism10
- Gastroenterology & Hepatology7
- Public & Global Health4
- Cell & Molecular Biology30
- Immunology & Inflammation14
- Neuroscience14
- Psychiatry & Mental Health8
- Genomics & Bioinformatics29
- Pharmacology & Drug Discovery5
- Microbiology & Mycology34
- Oncology22
- Ecology & Evolution5
- Protected Cropping & Horticultural Science5
- Plant Physiology & Photobiology19
- Student Research1
